MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 18.04.2026
Galapagos NV Anteile 2011-2026 | GLPG
Anteile Jährlich Galapagos NV
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 65.5 M | 65.1 M | 57.6 K | 52.1 M | 49.5 M | 944 M | 35.7 M | 30.1 M | 28.8 M | 26.5 M | - |
Alle Zahlen in EUR-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 944 M | 57.6 K | 130 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
BioNTech SE
BNTX
|
244 M | $ 95.5 | -3.88 % | $ 27.2 B | Germany |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
4.28 M | - | - | $ 269 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
21.6 M | - | - | $ 231 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
166 M | $ 22.35 | 0.72 % | $ 3.7 B | USA |
 |
Grifols, S.A.
GRFS
|
682 M | $ 8.27 | 0.49 % | $ 6.83 B |  Spain |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 3.5 | 5.42 % | $ 5.76 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
InflaRx N.V.
IFRX
|
41.6 M | $ 1.97 | -7.51 % | $ 152 M | Germany |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
19.2 M | - | -0.23 % | $ 916 M | USA |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 23.42 | -0.3 % | $ 2.98 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
68 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
33.4 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
25.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M | USA |
 |
Innate Pharma S.A.
IPHA
|
79.5 M | $ 1.4 | -2.1 % | $ 235 M | France |
 |
CRISPR Therapeutics AG
CRSP
|
89.9 M | $ 52.38 | -2.24 % | $ 4.71 B |  Schweiz |
 |
Avenue Therapeutics
ATXI
|
3.13 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.64 | 4.46 % | $ 436 M | Britain |
 |
Inventiva S.A.
IVA
|
39.2 M | $ 5.42 | 2.85 % | $ 138 M | France |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
Завод ДИОД
DIOD
|
91.5 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
301 M | - | - | - | Russia |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |